The following information comes from DailyMed, an FDA label information provider.
Clinical Trial Experience
Adverse events reported in >1% of patients receiving albuterol sulfate inhalation solution and more frequently than in patients receiving placebo in a four-week double-blind study are listed in the following table.
|1.25 mg Albuterol Sulfate Inhalation Solution(N=115)||0.63 mg Albuterol Sulfate Inhalation Solution(N=117)||Placebo(N=117)|
There was one case of ST segment depression in the 1.25 mg albuterol sulfate inhalation solution treatment group.
No clinically relevant laboratory abnormalities related to albuterol sulfate inhalation solution administration were seen in this study.
Metabolic acidosis has been reported after the use of albuterol sulfate inhalation solution. Because this reaction is reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate its frequency or establish a causal relationship to drug exposure.